Alto Neuroscienc Stock Price, News & Analysis

Alto Neuroscience (NYSE: ANRO) said members of management will present at two investor conferences in November 2025: the Stifel 2025 Healthcare Conference (Nov 11-13) with a fireside chat and one-on-ones on Nov 12, 2025 at 10:00-10:30 AM ET in New York, and the Jefferies London Healthcare Conference (Nov 17-20) with a fireside chat and one-on-ones on Nov 17, 2025 at 3:30-3:55 PM GMT in London.

Presentations will be available via live webcast on Alto's Investors "Events and Presentations" page, with a replay accessible after the events.

Alto Neuroscience (NYSE: ANRO) entered a private placement (PIPE) to raise approximately $50 million in gross proceeds, led by Perceptive Advisors with participation from several biotech investors.

Alto is selling 3,832,263 common shares at $5.914 per share and issuing pre-funded warrants to buy up to 4,622,251 shares at $5.9139 each (exercise price $0.0001). The PIPE is expected to close on October 21, 2025 and was priced at-the-market under NYSE rules.

Proceeds are earmarked to accelerate development of ALTO-207 for treatment resistant depression after a successful FDA meeting; Alto expects to start a Phase 2b by mid-2026 and now also expects to initiate a Phase 3 by early 2027.

Alto Neuroscience (NYSE: ANRO) announced plans to accelerate development of ALTO-207 for treatment resistant depression after a successful FDA meeting and a $50 million private placement to support expanded development. The company expects to initiate a Phase 2b potentially pivotal trial by mid-2026 and to begin a Phase 3 study by early 2027 pending Phase 3 readiness and protocol alignment with the FDA. Alto reported blinded PK results showing 96% PK-positive samples for ALTO-100 and 100% for ALTO-101, and it now guides cash runway into 2028 while adding ALTO-207 activities. Topline data for ALTO-101 remain expected in 1Q 2026.

Alto Neuroscience (NYSE: ANRO) announced on October 3, 2025 that the U.S. FDA granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). ALTO-101 is a novel PDE4 inhibitor that increased cAMP and showed pro‑cognitive effects in healthy volunteers in Phase 1, with significant effects on EEG measures and cognitive performance. Enrollment is ongoing in a Phase 2 proof-of-concept study in patients with CIAS. Fast Track status may enable more frequent FDA interactions and potential eligibility for accelerated approval or priority review if criteria are met.

Alto Neuroscience (NYSE:ANRO) announced positive results from an independent replication study validating EEG biomarkers in schizophrenia patients. The study confirmed that theta-band inter-trial coherence (ITC) effectively distinguishes individuals with schizophrenia from healthy controls.

The analysis, involving 155 schizophrenia patients and 272 healthy controls, demonstrated that theta ITC and event-related spectral perturbation (ERSP) showed the strongest case-control differences (Cohen's d = 0.64 and 0.78, respectively; p < 0.001). Both measures significantly correlated with processing speed, a key cognitive impairment indicator in schizophrenia.

These findings support Alto's use of theta ITC as a primary outcome measure in their ongoing Phase 2 trial of ALTO-101, a PDE4 inhibitor being developed for cognitive impairment associated with schizophrenia (CIAS).

Alto Neuroscience (NYSE:ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in four upcoming investor conferences in August and September 2025.

The company will participate in the H.C. Wainwright Biotech Breakthroughs Panel (August 21), H.C. Wainwright Global Investment Conference (September 9), Baird Global Healthcare Conference (September 10), and TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (September 17). The presentations will include panel discussions, fireside chats, and one-on-one investor meetings.

All available presentations will be webcast live on Alto's investor relations website, with replays available afterward.

Alto Neuroscience (NYSE:ANRO) reported Q2 2025 financial results and pipeline updates. The company acquired ALTO-207, a potentially best-in-class dopamine agonist combination product for treatment-resistant depression (TRD), with a planned Phase 2b pivotal trial expected by mid-2026. Alto maintains a strong cash position of $148.1 million, expected to fund operations into 2028 and through four upcoming clinical readouts.

Key pipeline developments include ongoing trials for ALTO-101 in schizophrenia (topline data 2H 2025), ALTO-300 in major depressive disorder (data mid-2026), and ALTO-100 in bipolar depression (data 2H 2026). Q2 2025 financial results showed R&D expenses of $13.1 million and a net loss of $17.7 million.

Alto Neuroscience (NYSE:ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has appointed Dr. Raymond Sanchez to its Board of Directors effective August 12, 2025.

Dr. Sanchez brings over 20 years of strategic experience in life sciences and currently serves as Senior Advisor at Bain Capital Life Sciences. His extensive background includes roles as Chief Medical Officer at Cerevel Therapeutics and senior positions at Otsuka Pharmaceutical. The appointment comes as Alto prepares to initiate its potentially pivotal Phase 2b trial of ALTO-207.

A psychiatrist by training and former Chief Resident at Yale School of Medicine, Dr. Sanchez's expertise in CNS drug development aligns with Alto's mission to revolutionize neuropsychiatric treatment through precision medicine approaches.

Alto Neuroscience (NYSE: ANRO) announced the publication of the PAX-D study results in The Lancet Psychiatry, evaluating pramipexole for treatment-resistant depression (TRD). The study, conducted by the University of Oxford and funded by the UK's National Institute for Health and Care Research, demonstrated significant clinical benefits.

The study showed that pramipexole augmentation of antidepressant treatment at a 2.5mg target dose achieved a large reduction in symptoms (Cohen's d=0.87) compared to placebo at 12 weeks, although it was associated with high adverse effects. These findings informed Alto's acquisition of ALTO-207, a fixed-dose combination of pramipexole and ondansetron, designed to maintain efficacy while reducing side effects.

Alto plans to initiate a potentially pivotal Phase 2b trial of ALTO-207 by mid-2026, collaborating with the National Health Service and PAX-D clinical sites. The company aims to leverage its proprietary dopamine biomarker insights in depression to optimize the treatment approach.